Deazaneplanocin A Is a Promising Drug to Kill Multiple Myeloma Cells in Their Niche.
Gaudichon J et al. PLoS One. 2014 Sep 25;9(9):e107009. doi: 10.1371/journal.pone.0107009. eCollection 2014.

HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
Borsi E et al. Exp Cell Res. 2014 Sep 25. pii: S0014-4827(14)00423-6. doi: 10.1016/j.yexcr.2014.09.018. [Epub ahead of print].

SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy.
Roccaro AM et al. Cell Rep. 2014 Sep 24. pii: S2211-1247(14)00718-9. doi: 10.1016/j.celrep.2014.08.042. [Epub ahead of print].

Antitumor effects of tyropeptin-boronic acid derivatives: new proteasome inhibitors.
Momose I et al. Cancer Sci. 2014 Sep 23. doi: 10.1111/cas.12542. [Epub ahead of print].

Destabilization of Akt Promotes the Death of Myeloma Cell Lines.
Zhang Y et al. Biomed Res Int. 2014;2014:190629. Epub 2014 Aug 31.

Low-energy laser irradiation promotes cellular damage in Glucocorticoids-resistant Multiple Myeloma cells.
Allegra A et al. Leuk Lymphoma. 2014 Sep 22:1-13. [Epub ahead of print].

Differential and limited expression of mutant alleles in multiple myeloma.
Rashid NU et al. Blood. 2014 Sep 18. pii: blood-2014-04-569327. [Epub ahead of print].

Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma.
Erickson SW et al. Blood. 2014 Sep 18;124(12):2001-3. doi: 10.1182/blood-2014-07-586701.

MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the anti-myeloma benefit of bortezomib.
Jagannathan S et al. Leukemia. 2014 Sep 19. doi: 10.1038/leu.2014.279. [Epub ahead of print].

Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2/Mcl-1 pathway.
Sadahira K et al. Int J Oncol. 2014 Sep 15. doi: 10.3892/ijo.2014.2652. [Epub ahead of print].

NEK2 mediates ALDH1A1 induced drug-resistance in multiple myeloma.
Yang Y et al. Oncotarget. 2014 Sep 2. [Epub ahead of print].

pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels.
Geeleher P et al. PLoS One. 2014 Sep 17;9(9):e107468. doi: 10.1371/journal.pone.0107468. eCollection 2014.

Crosstalk between microRNA30a/b/c/d/e-5p and the Canonical Wnt Pathway: Implications for Multiple Myeloma therapy.
Zhao JJ et al. Cancer Res. 2014 Sep 16. [Epub ahead of print].

Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.
Yu T et al. Cell Res. 2014 Sep 16. doi: 10.1038/cr.2014.122. [Epub ahead of print].

GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis.
Coleman EA et al. Support Care Cancer. 2014 Sep 14. [Epub ahead of print].

Pyk2 promotes tumor progression in multiple myeloma.
Zhang Y et al. Blood. 2014 Sep 12. pii: blood-2014-03-563981. [Epub ahead of print].

A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A et al. Clin Cancer Res. 2014 Sep 11. pii: clincanres.0847.2014. [Epub ahead of print].

A Bim-targeting strategy overcomes adaptive bortezomib-resistance in multiple myeloma through a novel link between autophagy and apoptosis.
Chen S et al. Blood. 2014 Sep 10. pii: blood-2014-03-564534. [Epub ahead of print].

Gene Expression Profiling Identifies IRF4-Associated Molecular Signatures in Hematological Malignancies.
Wang L et al. PLoS One. 2014 Sep 10;9(9):e106788. doi: 10.1371/journal.pone.0106788. eCollection 2014.

Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model.
Reagan MR et al. Blood. 2014 Sep 9. pii: blood-2014-02-558007. [Epub ahead of print].

MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications.
Sewastianik T et al. Biochim Biophys Acta. 2014 Sep 6. pii: S0304-419X(14)00080-8. doi: 10.1016/j.bbcan.2014.08.006. [Epub ahead of print].

Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma.
Robert F et al. Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13421-6. doi: 10.1073/pnas.1402650111. Epub 2014 Sep 2.

T cell-based targeted immunotherapies for patients with multiple myeloma.
Wang L et al. Int J Cancer. 2014 Sep 6. doi: 10.1002/ijc.29190. [Epub ahead of print].

Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation.
Popovic R et al. PLoS Genet. 2014 Sep 4;10(9):e1004566. doi: 10.1371/journal.pgen.1004566. eCollection 2014.

Activation of LTBP3 Gene by a LncRNA MALAT1 Transcript in Mesenchymal Stem Cells from Multiple Myeloma.
Li B et al. J Biol Chem. 2014 Sep 3. pii: jbc.M114.572693. [Epub ahead of print].

Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells.
Feng M et al. J Drug Target. 2014 Sep 4:1-8. [Epub ahead of print].

Resistance to Chemotherapy: Patient Variability and Cellular Heterogeneity.
Kessler DA et al. Cancer Res. 2014 Sep 1;74(17):4663-4670.

Resistance to Chemotherapy: Patient Variability and Cellular Heterogeneity.
Kessler DA et al. Cancer Res. 2014 Sep 1;74(17):4663-4670.

Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737.
Gu D et al. PLoS One. 2014 Sep 2;9(9):e103015. doi: 10.1371/journal.pone.0103015. eCollection 2014.

Targeting phospho-MARCKS overcomes drug resistance and induces antitumor activity in preclinical models of Multiple Myeloma.
Yang Y et al. Leukemia. 2014 Sep 2. doi: 10.1038/leu.2014.255. [Epub ahead of print].

The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Gan ZY et al. Eur J Haematol. 2014 Sep 2. doi: 10.1111/ejh.12436. [Epub ahead of print].

Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
Ju D et al. Mol Med Rep. 2014 Nov;10(5):2609-12. doi: 10.3892/mmr.2014.2522. Epub 2014 Aug 28.

Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor AZD8055 in Multiple Myeloma.
Cirstea D et al. Mol Cancer Ther. 2014 Aug 29. pii: molcanther.0147.2014. [Epub ahead of print].

Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking.
Martin-Antonio B et al. Cell Death Differ. 2014 Aug 29. doi: 10.1038/cdd.2014.120. [Epub ahead of print].

Absolute Quantification of Histone PTM Marks by MRM-Based LC-MS/MS.
Gao J et al. Anal Chem. 2014 Sep 8. [Epub ahead of print].

Round cell tumors of bone: an update on recent molecular genetic advances.
Wei S et al. Adv Anat Pathol. 2014 Sep;21(5):359-72. doi: 10.1097/PAP.0000000000000036.

Rush hour traffic: directing T cells to tumor.
Neelapu SS et al. J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju301. doi: 10.1093/jnci/dju301. Print 2014 Nov